What is the KPV peptide? The research and its FDA status

Quick answer KPV is a tiny fragment, three amino acids long, of a hormone your body makes called alpha-MSH, and the research on it so far is in cells and animals, not people. In July 2026 an FDA advisory committee reviewed it as a cream or gel, and news reports say the committee recommended adding it to the list of ingredients pharmacies may compound, against the advice of FDA's own staff. Today nothing has changed: KPV is not FDA-approved and not on that list, so licensed pharmacies can't compound it. What to watch for is a proposed rule from FDA, and there wasn't one as of October 2026.

What is KPV?

The name is the one-letter code of its three amino acids: K for lysine, P for proline and V for valine. That sequence is amino acids 11 to 13, the tail end, of alpha-melanocyte-stimulating hormone, or alpha-MSH (Getting and colleagues, 2003). FDA describes alpha-MSH as a hormone made in the pituitary gland, and KPV as a fragment of it that is also produced naturally in the body. Alpha-MSH is involved in skin coloring and other signaling.

KPV is a common name, not an official one. FDA's briefing says it found different salts and derivatives, including different active forms, sold commercially under the same name, and treats that as a patient-safety concern. Being so small makes KPV easy to make in a lab. It doesn't make it well understood in people.

Research on a whole hormone doesn't automatically apply to a fragment of it. One 2003 study found the two behave differently.

What the research measured

Everything published on KPV that we could find is laboratory and animal work.

• FDA's July 2026 review found no study in which KPV was given to people, by any route.
• The two journal papers behind this article tested it in mice and in cultured cells, and mostly asked how it acts.
• FDA found no toxicity studies of any kind, and no data on how the body absorbs and clears it apart from one skin test.

What each piece of work looked at:

• Mice and macrophages. Researchers compared KPV with other alpha-MSH fragments in mice with chemically induced inflammation of the abdominal cavity (peritonitis), giving the peptides systemically, and in cultured macrophages. They concluded that KPV acts differently from the main alpha-MSH fragments and is unlikely to work through the receptors alpha-MSH uses (Getting and colleagues, 2003).
• Human cell lines and mice. Researchers tested KPV in human intestinal cell lines and human T cells in the laboratory, and in two chemical models of colitis in mice, with KPV added to the drinking water. They proposed that a transporter called PepT1 carries it into cells (Dalmasso and colleagues, 2008).
• The nomination FDA reviewed. It cited nine references: eight animal studies of alpha-MSH derivatives and one skin-permeation study using donated human skin. FDA's summary of that study says KPV did not pass through skin well on its own.

Neither journal paper tested KPV as a treatment in people. Full citations are in the Sources list below.

Why licensed pharmacies can't compound KPV

KPV is not an FDA-approved drug and is not on FDA's 503A bulks list, so licensed pharmacies can't compound it; FDA removed it from its interim Category 2 on April 22, 2026 after the nominators withdrew their nominations, which FDA says is not a decision about the substance (how the categories work). In July 2026 FDA's reviewers proposed against adding it to the list, news reports (CNN and AJMC, July 31, 2026) say the advisory committee voted to recommend adding it anyway, and only a final rule after notice-and-comment rulemaking would change that, with no proposed rule published as of October 6, 2026 (the vote and the rulemaking path).

Is this right for me?

Today, no. No licensed pharmacy can compound KPV, so no provider can prescribe it through a lawful pharmacy, whatever your health history. Only a final FDA rule changes that.

What you can do now:

• Hear about it first. The sign-up at the end of this page carries availability news, nothing else.
• Talk to your own doctor about the skin or gut problem that brought you here. FDA's reviewers noted that approved treatments already exist for the conditions they reviewed.
• Pass on "research use only" products. FDA has written that such a label doesn't stop a product sold for people from being treated as a drug.

If FDA's rules ever change, an independent licensed provider in your state would still review your health history and decide. The answer may be no.

How it works

1. Enter your email below. The form at the end of this page asks for your email address and state, and nothing about your health.
2. Hear from us only if it becomes available through a licensed provider. We write about availability and nothing else, and you can unsubscribe anytime.
3. A licensed provider still decides. Being on the list is not a reservation or a prescription. If FDA's rules change, a provider licensed in your state reviews your health history first and can decline.

FAQ

Is KPV FDA-approved? No. FDA's briefing says it is not a component of any FDA-approved drug.

Is KPV just alpha-MSH in a smaller form? No. It is the last three amino acids of alpha-MSH. A fragment and a full hormone are different molecules, and a 2003 mouse and cell study found they act differently.

Can a doctor prescribe KPV? A prescription doesn't create a lawful source. Licensed pharmacies can't compound it, and that would take a final rule adding it to the bulks list. FDA also keeps an interim Category 1 for substances under evaluation, and KPV is not in it.

Did the FDA committee approve KPV? No. An advisory committee can only recommend, and FDA's own staff proposed against adding it.

When could it become available? No one can give a date. A proposed rule in the Federal Register would be the first real sign.

What this means for you

As of October 2026, licensed pharmacies can't legally compound KPV for patients: it isn't on FDA's 503A bulks list, and only FDA rulemaking changes that. If FDA lists it one day, the legal route would be a prescription from a licensed provider in your state, filled by a licensed pharmacy; compounded medications are not FDA-approved. Until then, products sold online as "research use only" aren't made for people.

The July 2026 FDA peptide vote, explained covers all seven peptides the committee reviewed and what has to happen next.

Safety information

FDA's safety page (content current as of April 22, 2026) says, word for word: "FDA has not identified any human exposure data on drug products containing KPV administered via any route of administration. FDA lacks important information regarding any safety issues raised by KPV, including whether it would cause harm if administered to humans."

• Unknown risks. FDA's July 2026 briefing says the potential safety risks in humans are unknown. It could not assess the risk of immune reactions or of the peptide clumping together, because no data were available.
• No reports is not no problems. FDA found no adverse-event reports in its main reporting database, and cautions that reporting is voluntary and compounded products are seldom reported.
• Quality. The nomination came with no certificate of analysis, and there is no public quality testing for impurities, clumping or microbial content.
• "Research use only" products. Websites offer KPV in oral, injectable, topical and nasal-spray forms; FDA reviewed only a cream and gel. FDA has said in writing that a "research use only" label doesn't change its view when a seller's website shows the product is meant for people. Products sold online as "research use only" are a different, unregulated market that Everlon does not participate in and that carries additional dangers.
• If you've used it and have a reaction, tell a doctor and report it to FDA's MedWatch.

If this is a medical emergency, call 911.

Sources

• Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. Journal of Pharmacology and Experimental Therapeutics. 2003;306(2):631-7. PMID: 12750433. PubMed, accessed 2026-10-06 (abstract only)
• Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-78. PMID: 18061177. PubMed, accessed 2026-10-06 (abstract only)
• FDA. FDA Briefing Document: KPV-related bulk drug substances (KPV free base and KPV acetate). Pharmacy Compounding Advisory Committee, July 23-24, 2026. fda.gov, accessed 2026-10-06
• FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026). fda.gov, accessed 2026-10-06
• FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (archived copy, content current as of 09/27/2024; KPV in Category 2 from September 29, 2023). web.archive.org, accessed 2026-10-06
• FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (interim categories list). Updated May 14, 2026. fda.gov, accessed 2026-10-06
• FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (content current as of 05/14/2026). fda.gov, accessed 2026-10-06
• FDA. Guidance for industry: Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act (January 2025). fda.gov, accessed 2026-10-06
• FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov, accessed 2026-10-06
• FDA. Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments. Federal Register. 2026;91:20465. FR Doc. 2026-07361, Docket FDA-2025-N-6895. April 16, 2026. federalregister.gov, accessed 2026-10-06
• FDA. Warning Letters (index; the five CDER letters to online peptide sellers dated August 24, 2026, posted September 1, 2026). fda.gov, accessed 2026-10-06
• CNN. FDA advisers support easing restrictions on six peptides. Here's what those drugs are and what happens next. July 31, 2026 (news report). cnn.com, accessed 2026-10-06
• AJMC. FDA Panel Backs 6 Peptides for Compounding. July 31, 2026 (news report). ajmc.com, accessed 2026-10-06
• 21 CFR 216.23, Bulk drug substances that can be used to compound drug products in accordance with section 503A. ecfr.gov, accessed 2026-10-06
• 21 U.S.C. 353a, Pharmacy compounding (2023 edition). govinfo.gov, accessed 2026-10-06